A population based randomised controlled trial of Helicobacter pylori eradication: impact on dyspepsia, quality of life and health

ISRCTN ISRCTN44816925
DOI https://doi.org/10.1186/ISRCTN44816925
Secondary identifying numbers LIP/H2B/001
Submission date
03/08/2006
Registration date
29/08/2006
Last edited
23/04/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Athene Lane
Scientific

University of Bristol
Canynge Hall
Whiteladies Road
Bristol
BS8 2PR
United Kingdom

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study acronymHEALTH
Study objectivesTo determine the impact of a community-based Helicobacter pylori screening and eradication programme on the incidence of dyspepsia, resource use and Quality of Life (QoL), including a cost-consequences analysis.
Ethics approval(s)Gained ethics approval from Frenchay Hospital LREC (reference number: 95/83 20/01/1996).
Health condition(s) or problem(s) studiedDyspepsia
InterventionSubjects were screened for H. pylori. Those who were positive were randomised between active eradication therapy or a placebo. Subjects were not randomised if they were found to be uninfected with H. pylori.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Helicobacter pylori
Primary outcome measureDyspepsia resolution at two years after randomisation.
Secondary outcome measures1. Reduction in health service utilisation
2. Quality of life
Overall study start date01/05/1996
Completion date01/05/2006

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants1550
Key inclusion criteria1. Aged 20 to 59 years, male and female
2. Able to give written informed consent
Key exclusion criteriaAny persons with the following conditions: pregnancy, breast feeding, severe renal impairment, adverse reaction to macrolide antibiotics, concurrent medication with wafarin, theophyllin, digoxin, terfendine, carbemazepine, ergot derivatives, bismuth compounds, acute porphyria.
Date of first enrolment01/05/1996
Date of final enrolment01/05/2006

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

University of Bristol
Bristol
BS8 2PR
United Kingdom

Sponsor information

NHS (South and West) (UK)
Government

Westward House
Lime Kiln Close
Stoke Gifford
Bristol
BS12 6SR
United Kingdom

Website http://www.bristolswpct.nhs.uk/

Funders

Funder type

Government

NHS Executive (south and west)

No information available

Glaxo Wellcome UK

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results: 12/06/2004 Yes No
Results article results: 28/01/2006 Yes No
Results article results: 15/04/2008 Yes No